Although pre-clinical experiments associate cannabinoids with reduced depressive symptoms, there is a paucity of clinical evidence. This study aims to analyze the health-related quality of life changes and safety outcomes in patients prescribed cannabis-based medicinal products (CBMPs) for depression.
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2023-01-06 15:02:172023-01-06 15:06:56Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry
Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2–3 weeks or more. In the clinic, the speed of beginning of the actions of antidepressant drugs or other interventions is vital for many reasons.
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Nikhil Jainhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngNikhil Jain2022-08-11 07:15:562022-08-11 08:44:29Rapid treatments for depression: Endocannabinoid system as a therapeutic target
Little is known about cannabis use for insomnia in individuals with depression, anxiety, and comorbid depression and anxiety. To develop a better understanding of distinct profiles of cannabis use for insomnia management, a retrospective cohort study was conducted on a large naturalistic sample.
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Nikhil Jainhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngNikhil Jain2022-08-11 06:53:522022-08-11 08:40:58An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample
Major depressive disorder is a high-impact, debilitating disease and it is currently considered the most prevalent mental illness. It is associated with disability, as well as increased morbidity and mortality. Despite its significant repercussions in our society, its exact pathophysiology remains unclear and therefore, available antidepressant treatment options are limited and, in some cases, ineffective. In the past years, research has focused on the development of a multifactorial theory of depression. Simultaneously, evidence supporting the role of the endocannabinoid system in the neurobiology of neuropsychiatric diseases has emerged. Studies have shown that the endocannabinoid system strongly impacts neurotransmission, and the neuroendocrine and neuroimmune systems, which are known to be dysfunctional in depressive patients. Accordingly, common antidepressants were shown to have a direct impact on the expression of cannabinoid receptors throughout the brain. Therefore, the relationship between the endocannabinoid system and major depressive disorder is worth consideration. Nevertheless, most studies focus on smaller pieces of what is undoubtedly a larger mosaic of interdependent processes. Therefore, the present review summarizes the existing literature regarding the role of the endocannabinoid system in depression aiming to integrate this information into a holistic picture for a better understanding of the relationship between the two.
https://www.cannabisclinicians.org/wp-content/uploads/2021/01/cannabis-nomenclature-kenzi-riboulet-zimouli-1.jpg8001200Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2022-03-14 15:40:082022-03-14 15:40:35Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression
Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system….
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Michelle Smithhttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngMichelle Smith2020-11-16 08:05:002020-12-04 12:11:17FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1
Authors: Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, Manuel Guzmán European Neuropsychopharmacology, 10 February 2020
— Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2020-02-10 08:49:252020-03-24 09:08:11Possible therapeutic applications of cannabis in the neuropsychopharmacology field.
Authors: Ewa Poleszak, Sylwia Wośko, Karolina Sławińska, Aleksandra Szopa, Andrzej Wróbel, Anna Serefko Life Sciences, 15 November 2018
— Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and others have been suggested. It seems that the endocannabinoid system is also inv…
Authors: Jean Y. Ko, Van T. Tong, Jennifer M. Bombard, Donald K. Hayes, John Davy, et al Drug and Alcohol Dependence, June 2018
— BACKGROUND: We sought to describe the correlates of marijuana use during and after pregnancy, and to examine the independent relationship between prenatal marijuana use and infant outcomes. STUDY DESIGN: We used state-specific data from the Pregnancy Risk Assessment Monitoring…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2018-06-01 11:14:472020-03-19 10:54:46Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study.
Authors: Susan A. Stoner Alcohol & Drug Abuse Institute, University of Washington, June 2017
— THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…
Authors: Louise Arseneault, Mary Cannon, Richie Poulton, Robin Murray, Avshalom Caspi, Terrie E Moffitt BMJ, 23 November 2002
— The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…
https://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.png00Sarah Russohttps://www.cannabisclinicians.org/wp-content/uploads/2020/06/scc_logo-long-R-2-1.pngSarah Russo2002-11-23 07:40:362020-03-19 10:57:28Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.